Itoroxx

Etoricoxib, the active ingredient in Itoroxx, is a COX-2 selective NSAID presented as an oral tablet for oral use. It reduces pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain episodes, and gout, providing targeted relief for adult patients.

GNH USA supplies Itoroxx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Etoricoxib is indicated for several musculoskeletal and inflammatory conditions where COX‑2 mediated prostaglandin production contributes to pain and swelling. - Osteoarthritis: reduces joint pain and improves functional mobility. - Rheumatoid arthritis: alleviates synovial inflammation and joint discomfort. - Ankylosing spondylitis: diminishes spinal stiffness and pain. - Acute pain: provides rapid relief for short‑term painful episodes. - Gout: helps control pain and inflammation during acute attacks.

Etoricoxib may cause a range of adverse reactions, from mild to serious. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia - Headache - Dizziness - Elevated blood pressure - Peripheral edema - Skin rash

Serious or Rare Side Effects: - Cardiovascular thrombotic events (e.g., myocardial infarction, stroke) - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic enzyme elevations or liver injury - Acute renal impairment or failure - Anaphylactic reactions

Before prescribing Etoricoxib, clinicians should evaluate individual risk factors and monitor therapy closely. - Cardiovascular risk assessment: avoid in patients with uncontrolled hypertension or recent cardiovascular events. - Blood pressure monitoring: check regularly during treatment. - Renal function evaluation: adjust use in patients with impaired kidney function. - Use lowest effective dose: limit duration to the shortest period needed for symptom control. - Hypersensitivity screening: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Etoricoxib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other COX‑2 inhibitors: additive risk of cardiovascular and gastrointestinal toxicity. - Anticoagulants (e.g., warfarin): increased bleeding tendency. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): elevated Etoricoxib plasma levels.

Moderate Interactions (Monitor Closely): - Non‑selective NSAIDs: heightened gastrointestinal risk. - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may diminish antihypertensive effect and affect fluid balance.